Caron Nadine R, Sturgeon Cord, Clark Orlo H
Department of Surgery, University of California San Francisco and UCSF Comprehensive Cancer Center at Mount Zion, 1600 Divisadero Street, Hellman Building, Room C3-47, San Francisco, CA 94143, USA.
Curr Treat Options Oncol. 2004 Aug;5(4):335-45. doi: 10.1007/s11864-004-0024-4.
More than 95% of patients with primary hyperparathyroidism (HPT) will be cured at initial operation by an experienced surgeon. Despite this success rate, persistent and recurrent HPT remain challenging clinical entities. The most cost effective and safest treatment for persistent and recurrent HPT is avoidance by successful first operation. The contributors to treatment failure can be categorized into factors related to the initial surgical procedure, anatomic variability, and the biology of disease. An understanding of the factors that commonly contribute to treatment failure can help prevent persistent and recurrent disease and plays an integral role in planning subsequent surgical approaches. Once a biochemical diagnosis of persistent or recurrent HPT is confirmed, a thorough evaluation of previous operative, pathology, and radiology reports is essential. Localization procedures supplement this information and help direct the reoperative approach. When complementary noninvasive studies, such as ultrasound, sestamibi, and magnetic resonance imaging are negative, equivocal, or discordant, invasive tests (eg, selective venous sampling for parathyroid hormone levels) are warranted. Intraoperative ultrasound and gamma-probe localization are of questionable value, but intraoperative parathyroid hormone assays help facilitate these challenging repeat dissections. Repeat parathyroid exploration is associated with more complications and fewer cures compared to the initial explorations and should only be undertaken by an experienced surgeon in a center that can provide expert preoperative localization, adjunctive intraoperative tools, and cryopreservation of parathyroid tissue when necessary. Although controversy exists regarding indications for reoperative treatment for persistent or recurrent HPT, parathyroidectomy remains the only curative treatment option. Surgery should be considered first-line treatment in most circumstances.
超过95%的原发性甲状旁腺功能亢进症(HPT)患者在初次手术时可被经验丰富的外科医生治愈。尽管有这样的成功率,但持续性和复发性HPT仍然是具有挑战性的临床病症。对于持续性和复发性HPT,最具成本效益且最安全的治疗方法是通过首次成功手术来避免。治疗失败的因素可分为与初次手术操作、解剖变异以及疾病生物学相关的因素。了解通常导致治疗失败的因素有助于预防持续性和复发性疾病,并且在规划后续手术方法中起着不可或缺的作用。一旦确诊为持续性或复发性HPT的生化诊断,对既往手术、病理和放射学报告进行全面评估至关重要。定位检查可补充这些信息并有助于指导再次手术的方法。当超声、锝-99m甲氧基异丁基异腈(sestamibi)和磁共振成像等补充性非侵入性检查结果为阴性、不明确或不一致时,有必要进行侵入性检查(例如,选择性静脉采血检测甲状旁腺激素水平)。术中超声和γ探针定位的价值存疑,但术中甲状旁腺激素检测有助于促进这些具有挑战性的再次解剖。与初次探查相比,再次甲状旁腺探查相关的并发症更多,治愈率更低,并且应该仅由经验丰富的外科医生在能够提供专业术前定位、术中辅助工具以及必要时甲状旁腺组织冷冻保存的中心进行。尽管对于持续性或复发性HPT再次手术治疗的指征存在争议,但甲状旁腺切除术仍然是唯一的治愈性治疗选择。在大多数情况下,手术应被视为一线治疗方法。